Advisors Preferred LLC Sells 18,353 Shares of Cencora, Inc. $COR

Advisors Preferred LLC cut its stake in Cencora, Inc. (NYSE:COR) by 96.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 767 shares of the company’s stock after selling 18,353 shares during the quarter. Advisors Preferred LLC’s holdings in Cencora were worth $239,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of COR. United Bank increased its stake in shares of Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after acquiring an additional 305 shares during the period. First Citizens Bank & Trust Co. purchased a new stake in shares of Cencora during the 2nd quarter valued at approximately $216,000. Caitong International Asset Management Co. Ltd purchased a new stake in Cencora in the 2nd quarter valued at about $61,000. State of New Jersey Common Pension Fund D increased its holdings in Cencora by 7.3% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 59,449 shares of the company’s stock valued at $17,826,000 after purchasing an additional 4,043 shares during the last quarter. Finally, AG2R LA Mondiale Gestion D Actifs boosted its holdings in Cencora by 8.3% during the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 7,102 shares of the company’s stock valued at $2,130,000 after acquiring an additional 543 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.4%

Shares of COR stock opened at $360.70 on Monday. Cencora, Inc. has a 1-year low of $240.72 and a 1-year high of $377.54. The firm’s 50-day simple moving average is $349.41 and its 200-day simple moving average is $331.39. The firm has a market cap of $70.17 billion, a P/E ratio of 43.35, a PEG ratio of 1.68 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.73 earnings per share. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is 28.85%.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 15,220 shares of company stock worth $5,282,867. Company insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on COR shares. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Wells Fargo & Company increased their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. TD Cowen boosted their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $399.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.